Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SPTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSeaport Therapeutics reports Q1 2026 financial results
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
medium
Company announced financial results for the three months ended March 31, 2026 via press release. Specific financial metrics and performance data are contained in the attached exhibit.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings disclosure filed under Item 2.02 (Results of Operations and Financial Condition). The 8-K itself contains no financial details beyond the announcement.
8-K: Earnings view on EDGAR →
Summary
Seaport Therapeutics filed its routine quarterly earnings 8-K announcing first quarter 2026 financial results. The filing follows standard SEC practice where the company furnishes a press release as an exhibit rather than embedding financial details in the 8-K body itself. This is a procedural disclosure required for public companies.
For retail investors, the key information—actual revenue, expenses, cash position, and any operational updates—would be in the press release exhibit, which is not analyzed here. This filing simply confirms the company met its quarterly reporting obligations. Investors should review the full press release for Q1 performance metrics, cash runway, and any updates on clinical programs or business development. Watch for management commentary on trial timelines and funding needs in any accompanying earnings call.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 8, 2026, Seaport Therapeutics, Inc. (the "Company") announced its financial results for the three months ended March 31, 2026.
The company disclosed its first quarter 2026 financial results. The actual financial data is contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Seaport Therapeutics filed an 8-K attaching a press release dated June 8, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit | Number | Description | 99.1 | Press Release, dated June 8, 2026
The company attached a press release dated June 8, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature and materiality of any disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify